Johnson & Johnson is preparing next year to spin off its consumer health unit into a publicly traded company separate from its pharmaceutical and medical technology operations. Ahead of the split, Morgan Stanley put out a research note, highlighting some of the debates in the market over the move, which would result in a consumer brands company called Kenvue and a pharma company with the J & J moniker.
The company's approved and pending treatments for blood cancer and multiple myeloma are "underappreciated," Morgan Stanley said. The analysts added that the multiple myeloma market will grow to about $33 billion in 2030 — and by that time, J & J's therapies could take more than 80% of that market share.
Interesting...
will they both be called Johnson?
Is this to dodge the up and coming lawsuits?
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »
Source: CNBC - 🏆 12. / 72 Read more »